Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
11:30am, Friday, 20'th May 2022 GlobeNewswire Inc.
Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
07:30am, Friday, 20'th May 2022
Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
12:15pm, Thursday, 05'th May 2022 Zacks Investment Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
These stocks soared during the pandemic, and then crashed. Ten are now expected to double in price.
11:00am, Wednesday, 04'th May 2022 MarketWatch
The group rose at least 300% in the pandemic before crashing 70% or more.
5 Graham's Lost Formula Biotech Stocks to Consider for May
04:35pm, Tuesday, 03'rd May 2022
After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Surpass Estimates
11:45am, Tuesday, 03'rd May 2022 Zacks Investment Research
Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know
07:00pm, Monday, 02'nd May 2022 Zacks Investment Research
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
11:30am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
03:02pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
12:47pm, Tuesday, 19'th Apr 2022
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why
07:34pm, Monday, 18'th Apr 2022 Benzinga
TG Therapeutics Inc's (NASDAQ: TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leu
Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why
03:37pm, Monday, 18'th Apr 2022
TG Therapeutics Inc's (NASDAQ: TGTX) shares are plunging after new data showed that ublituximab /Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leu
10 Biggest Price Target Changes For Monday
11:41am, Monday, 18'th Apr 2022 Benzinga
Raymond James cut The Estée Lauder Companies Inc. (NYSE: EL) price target from $390 to $345. Estée Lauder shares rose 0.4% to $264.95 in pre-market trading.
HC Wainwright & Co. cut the price targe
TG Therapeutics: I May Double Down Again
11:00am, Monday, 18'th Apr 2022
TGTX withdrew its BLA/NDA for CLL due to OS complications. The stock may be hit hard on Monday.
TG Therapeutics to pull FDA submission for oncology drug; shares slid 24%
10:10am, Monday, 18'th Apr 2022
Shares of TG Therapeutics Inc. TGTX, -21.85% tumbled 24.2% in trading on Monday following the company's announcement on Friday that it had withdrawn an application to get Food and Drug Administration
